Here's a look at some of the top Wall Street stories for medical device companies this week: Medtronic updates on $43B Covidien deal financing; Boston Scientific, Bard CEOs cool on consolidation; Nevro sets range for IPO of up to $106m; Alere to sell Alere Health unit to Optum for $600m; Skyline Medical conducts 1-for-75 reverse stock split
Medtronic and Covidien say their pending, $43 billion merger is expected to close in early 2015.
Here's a look at some of the top regulatory stories for medical device companies this week: Covidien plans to sell some vascular therapies ahead of Medtronic merger; Covidien, Medtronic shares jump on affirmation of $43B merger; Wright Medical to acquire Tornier for $3.3B in inversion deal; Integra LifeSciences closes MicroFrance, Xomed buy from Medtronic; Globus Medical snaps up allograft maker Transplant Technologies
Medtronic launches a clinical trial to study a new replacement heart valve designed to be surgically implanted in patients with severe aortic stenosis.
Medtronic (NYSE:MDT) today said it launched a clinical trial for a new replacement heart valve designed for patients with severe narrowing of the aortic valve.
Here's a look at some of the top legal news stories for medical device companies this week: Ex-Boston Scientific engineer accused of stealing balloon catheter secrets; Jury clears DePuy in 1st Pinnacle bellwether trial; U.S. Patent Office denies Medtronic request in Endotach stent case; Jury deliberations begin in first trial over DePuy's Pinnacle hips; Johnson & Johnson's DePuy wins first trial over Pinnacle hips
Integra LifeSciences says it closed the $60 million buy of a pair of Medtronic's ear, nose & throat instrument lines.
Covidien says it plans to divest its some of its vascular therapies business to mollify U.S. anti-trust regulators about its proposed $43 billion merger with Medtronic.